Novo Nordisk A (NVO) Return on Equity ROE from the first quarter 2026 to first quarter 2025 and annually, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Novo Nordisk A  (NYSE: NVO)

Novo Nordisk A's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Novo Nordisk A in the first quarter 2026?
Novo Nordisk A achieved a return on average equity (ROE) of 66.16 % in its first quarter 2026, which is below Novo Nordisk A's average return on equity, which stands at 67.97%.

ROE has advanced compared to 54.35% in the fourth quarter 2025, due to net income growth.

Within the Major Pharmaceutical Preparations industry 9 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2025 from 133 to 136.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Equity Change 2.68 % 53.1 % 48.24 % 64.05 % -
Y / Y Net Income Change 85.56 % 5.49 % -22.09 % 39.24 % 10.81 %
Net Income (TTM) in Millions 19,025 15,518 15,296 16,184 15,049
Return On Equity (TTM) 66.16 % 54.35 % 59.04 % 68.19 % 71.16 %
NVO's Total Ranking # 136 # 133 # # #
Equity (TTM) in Millions 31,307 30,491 26,709 26,514 30,491
Seq. Equity Change 2.68 % 14.16 % 0.74 % -13.04 % 53.1 %
Seq. Net Income Change 78.62 % 35.94 % -22.25 % -1.72 % 1.54 %

Back to NVO Management Effectiveness >> NVO's 5 Years Annual ROE >> Compare NVO ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 10
Sector # 27
Overall # 136

Return On Equity Statistics
High Average Low
77 %
67.97 %
50.89 %
(Dec 31 2018)   (Dec 31 2025)





NVO Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 30,491 19,916 15,813 12,010 10,767
Y / Y Equity Change 53.1 % 25.95 % 31.67 % 11.54 % 3.45 %
Net Income in Millions 15,518 14,649 12,148 7,861 7,597
Y / Y Net Income Change 5.93 % 20.59 % 54.53 % 3.48 % 17.78 %
Return On Equity 50.89 % 73.56 % 76.82 % 65.46 % 70.56 %

Back to NVO Management Effectiveness >> NVO's 5 Years Annual ROE >> Compare NVO ROE to its Competitors




Annual Roe Comment
In 2025 ROE fell to 50.89 %, despite net income growth.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
NVO's' Return on Equity at Yahoo Finance
NVO's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for NVO's Competitors
Subscribers only: Roe for Novo Nordisk A's Suppliers
Subscribers only: Return On Equity for NVO's Customers




Companies with similar Return On Equity at Mar 31 2026, within Healthcare Sector ROE
Rigel Pharmaceuticals Inc  147.03 %
Fortress Biotech Inc   140.48 %
Arbutus Biopharma Corp  129.32 %
Halozyme Therapeutics Inc   126.27 %
Petros Pharmaceuticals inc   124.23 %
Advanced Biomed Inc.  121.71 %
Medpace Holdings Inc   120.89 %
Capforce Inc   110.42 %
Eli Lilly And Company  101.17 %
Qhslab Inc   91.63 %
Amgen Inc   89.41 %
Exelixis Inc   88.60 %
Entera Bio Ltd   87.97 %
Tg Therapeutics Inc   87.36 %
Alnylam Pharmaceuticals Inc   86.11 %
Zevra Therapeutics Inc   81.34 %
Pulmatrix Inc   78.57 %
Earth Science Tech Inc   71.44 %
Idexx Laboratories Inc  70.87 %
Elite Pharmaceuticals Inc   68.60 %
Escalon Medical Corp   66.85 %
3m Company  65.54 %
Aurinia Pharmaceuticals Inc   64.48 %
Lifemd Inc   63.70 %
Zoetis Inc   61.63 %
Vaxart Inc   61.43 %
Dariohealth Corp   60.52 %
Nrc Health  57.25 %
Oramed Pharmaceuticals Inc  55.40 %
Innoviva Inc   47.59 %

Date modified: 2026-09-30T13:42:16+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.